| SPEAKERS Professor Tan Eng Chye
National University of Singapore (NUS)
Deputy President (Academic Affairs) and Provost
Professor Tan Eng Chye is
Deputy President (Academic Affairs) and Provost at the
National University of Singapore.
As Deputy President and Provost, he oversees and drives
special strategic initiatives of critical importance for
the University. His responsibilities include proposing
the budget and resource allocation plan for the academic
cluster; overseeing NUS Deans and their Faculties/
Schools; providing strategic directions and setting
academic policies. He also has oversight of the
development and implementation of new educational
programmes and initiatives; and is responsible for
educational quality assurance, overseeing admission
policies and processes to ensure best quality enrolments.
Professor Tan is responsible for the appointment,
promotion and tenure process, as well as the reward and
incentive systems for academic staff.
Professor Tan has held positions of administrative
leadership at Faculty and Department levels. He was Dean
of Science from June 2003 to March 2007. Other positions
included Chairman, Faculty Promotion and Tenure Committee
from July 2001 to June 2003; Vice-Dean (Academic
Affairs), Faculty of Science from July 1999 to June 2003;
and Sub-Dean, Faculty of Science from July 1994 to August
1996 and from July 1998 to June 1999. He was also Deputy
Head, Department of Mathematics from July 1999 to June
2000.
Currently, Professor Tan chairs the Management Board of
the Risk Management Institute, NUS; and has been a member
of the Management Boards of the Defence Science National
Laboratories, MINDEF; Institute for Mathematical
Sciences, NUS; Management Board, Singapore MIT Alliance
and the MINDEF-NUS Temasek Laboratories, MINDEF.
Professor Tan is also a Council member of the National
Institute of Education, NTU.
Dr Beh Swan Gin
Executive Director
Biomedical Research Council, Agency for Science,
Technology & Research
Assistant Managing
Director
Planning and Policy, Singapore Economic Development
Board.
Dr Beh, an Administrative Service officer, was appointed
as Executive Director of the Biomedical Research Council
at the Agency for Science, Technology & Research on 1
October 2006. He is concurrently Assistant Managing
Director for Planning and Policy at the Singapore
Economic Development Board.
Prior to this, Dr Beh was Director Biomedical Sciences,
which is the group responsible for attracting biomedical
investments to Singapore and for developing the
Biomedical Sciences industry cluster. He was concurrently
Director of EDB’s North American Operations, as well
as Director of the Ministry of Trade &
Industry’s Energy Planning Division. He relinquished
the latter appointment on 31 December 2006.
Dr Beh graduated as a Sloan Fellow from Stanford
University’s Graduate School of Business in July
2001. He was Regional Director of EDB’s Eastern US
Operations from July 1998 to July 2000. In that job, he
was responsible for EDB’s offices in New York,
Boston and Washington DC, and covered Eastern Canada and
Eastern United States. He started his EDB career in
November 1992.
Dr Beh is a medical doctor by training and graduated from
the National University of Singapore in March 1991. He is
on the Board of Directors for Singapore Health Services
Pte. Ltd. as well as for International Enterprise
Singapore.
Dr Lily Chan
Chief Executive Officer
National University of Singapore Enterprise
Dr Lily Chan, as Chief
Executive Officer of NUS Enterprise, leads the
organization with a vision to inject an enterprise
dimension to NUS teaching and research involving the
University's students, staff and alumni. In particular,
Dr Chan spearheads strategies and initiatives to promote
industry collaboration and business ventures for the
University. She oversees the functions of the Enterprise
Cluster which complements the academic cluster of the
University to nurture talents with an entrepreneurial and
global mindset. The Enterprise Cluster comprises NUS
Technology Holdings Pte Ltd, NUS Overseas Colleges, NUS
Entrepreneurship Centre, NUS Industry Liaison Office, NUS
Extension and NUS Publishing.
Dr Chan has more than 25 years of biomedical industry
experiences, which include initiating start-ups, venture
investments and active Board involvements in many biotech
companies. Prior to joining NUS, she was the Managing
Director, of Bio*One Capital Pte Ltd, an investment arm
of the Singapore Economic Development Board, with focus
in expanding the growth of biomedical science industry in
Singapore.
Obtaining her PhD (Microbiology and Immunology) from the
University of Illinois at the Medical Center, Chicago,
Illinois, USA, Dr Chan started her career as a research
scientist with the NUS Department of Medicine. She
subsequently moved into industry, and over the years held
positions with increasing responsibilities.
Dr. Chan was the founding Co-Chairman of ES Cell
International Pte Ltd. Furthermore, she holds US patents
and has published in international journals.
Dr Paul Chapman
Director and Head
Centre for Research in Cognitive and Neurodegenerative
Disorders, GlaxoSmithKline
Paul Chapman is currently the Director and Site Head at
the GSK Centre for Research in Cognitive and
Neurodegenerative Disorders in Singapore. He has
published numerous articles related to Neuroscience in
established international journals.
Dr Paul Chapman studied Psychology at the Washington and
Lee University, USA. Following this, he went on to do his
PhD in Psychology at Stanford University, with a Minor in
Neuroscience.
He joined the Department of Psychology at Yale University
in 1988 as a Post-doctoral Fellow. In August 1989, Dr
Chapman joined the Department of Psychology, Graduate
Program in Neuroscience, University of Minnesota as
Assistant Professor and later, Associate Professor. From
December 1995, he moved to the Cardiff School of
Biosciences at Cardiff University where he was Professor
of Neuroscience.
Dr Chapman became Senior Investigator in the Department
of Molecular and Cellular Neuroscience at Merck Sharpe
& Dohme in February 2003. Then in April 2005, he
moved to his present position in GlaxoSmithKline,
Singapore.
Mr Harry Lam
Director of Operations,
Genentech Singapore Product Operations
Dr. Harry Lam is the
Director of Operations, Genentech Singapore Product
Operations. Before joining Genentech in 1996, he spent
eleven years in the Bioprocess R&D department at
Pfizer Central Research, Groton, Connecticut. He has over
twenty years of experience in bioprocess R&D and
large-scale biochemical manufacturing operations.
He is the author or co-author of over twenty professional
journal papers and presentations, and four U.S. patents.
He is a member of the ACS Biochemical Technology
Division, ISPE, PDA, and ASTM E55 Committee.
Dr. Lam received a B.Sc. degree in Chemical Engineering
from University of Birmingham, U.K., and a Ph.D. degree
in Chemical Engineering from Rensselaer Polytechnic
Institute, Troy, New York.
Dr Michael
Brown
Vice President
Operations, Lonza Biologics Singapore Pte Ltd
Michael Brown is Vice
President of Operations for Lonza Biologics’ new
Biopharmaceutical production site in Singapore. Prior to
this role, Dr Brown was responsible for process scale-up
plus small scale clinical and commercial GMP
manufacturing of recombinant proteins and therapeutic
monoclonal antibodies at Lonza’s UK site. Previous
roles within Lonza have been based in Research and
Development specialising in fermentation optimisation of
mammalian cell cultures, primary separation technologies,
process transfer into manufacturing and scale-up of
processes from 200 to 20,000 L. Once a microbial
physiologist, Dr Brown had several roles in R&D at
Celltech Biologics and has a Ph.D. in Microbiology from
the University of Surrey, UK.
Mr Francois
Capit
General Manager
Bio-Rad Laboratories
Currently, Mr Francois
Capit is the General Manager of Asia Pacific Regional
Office, Bio-Rad. Prior to this in 2005, he was the Food
Science Division Manager of Bio-Rad France and in charge
of the management of the P&L of the Food Science
business on a Worldwide basis. He was also given direct
responsibility of the R&D, Marketing and Production
Development of the business market share and of the
product portfolio. Although he is not so much involved
Bio-Rad activities, he still handles the responsibility
of supervising and coordinating central functions, such
as IT, Purchasing and Communication of the French
activities.
He was a Member of the Pasteur Institut- Bio-Rad
Committee for Industrial Relations from 2003 to 2005.
Appointed as Operations Manager of Bio-rad France from
1999 until 2003, he took on the triple roles of
supervising and coordinating central functions, deciding
on the French sites' industrial policy and heading the
"non strategic product" division of medical
diagnosis. Previosly from 1989 to 1999, he was the
R&D Project Manager of Safoni.
Mr Francois holds a Master's degree in general economics
and management at Sorbonne-Paris I University. He is
fluent in French, Spanish and English, with some basic
knowledge German.
Mr Chris Dobson
Vice President & Managing Director,
GlaxoSmithKline (Glaxo Wellcome Manufacturing Pte Ltd,
Beecham Pharmaceuticals (Pte) Ltd and GSK Biologicals Pte
Ltd)
Chris Dobson is
responsible for the manufacturing operations on the
GlaxoSmithKline sites at Pioneer Sector 1 and Quality
Road in Singapore. He was appointed to this position on
25 September 2006.
He was previously Site Director for the GSK factory in
Melbourne, Australia from March 2004.
Chris joined Glaxo in 1986 and held positions as Site
Quality Assurance Manager for Ulverston and then Director
of Quality at the Jurong, Singapore factory. In 1999 he
was appointed Head of Quality Assurance for Primary
Supply and held similar positions until his appointment
as Site Director in Melbourne.
Chris graduated in Chemistry from Loughborough University
in the UK and prior to joining Glaxo spent five years
with Beecham and five years with Cyanamid of Great
Britain.
He has a wife, Janet with him in Singapore and a
24-year-old daughter and a 22-year-old son in the UK.
Chris enjoys walking, cycling, scuba diving and drinking
coffee in the sunshine.
Dr Michael
Schroter
Lilly Singapore Centre for Drug Discovery
Michael Schroter is the
Chief Operating Officer of Lilly Singapore Centre for
Drug Discovery (LSCDD), a wholly owned subsidiary of Eli
Lilly and Company. LSCDD focuses on drug discovery based
on adult stem cell and epigenetic research in the areas
of cancer and metabolic disorders. The Centre also
conducts biomarker discovery in these areas, and
scientific computational research and development in
support of therapeutic areas of interest to Lilly.
Prior to his current position Dr. Schroter was a member
of the Eli Lilly business development team in the US,
responsible for negotiating late stage in- and
outlicensing deals. Dr. Schroter was a co-founder and
director of Apotech in Switzerland (today TopoTarget and
Apotech Research) a biotech company specializing in drug
discovery related to apopotic signaling pathways.
Dr. Schroter holds a PhD from the University of Lausanne,
Switzerland and a MBA from IMD, Switzerland.
Dr Thomas Hies
Head, Research and Development and Process Development
Siemens Medical Instruments Pte Ltd
Dr. Thomas Hies is head of
Research and Development and Process Development (R&D
PD) of the Siemens Medical Instruments Pte Ltd in
Singapore. This is the biggest R&D location of the
Siemens Audiological Engineering Group outside of
Germany. Currently more than 80 R&D engineers (mainly
electrical, mechanical and SW engineers) working within.
Main tasks of the Singapore R&D location are the
development of world class hearing systems incl. SW,
advanced manufacturing engineering and design to
manufacturing.
Dr. Thomas Hies studied physics at the University of
Mainz and the Technical University of Berlin, Germany.
The diploma thesis is dealing with time series analysis
of air pollution data and modeling of the concentration
of air pollution in urban cities.
After achieving the diploma in physics in 1997 he joined
the ENT clinic at the University of Erlangen and was
working in the department of Phoniatrics &
Pedaudiology to investigate and establish methods to
determine objectively the hearing threshold and speech
discrimination of babies and small children. Basis of
these objective methods is the measurement and analysis
of the electrical brain signals.
After his PhD study Dr. Thomas Hies joined the Siemens
Audiological Engineering Group, the world biggest
manufacturer of hearing instruments, in 2000. He worked
within the basic research team investigating e.g. new
fitting methods of hearing instruments. In 2003 he took
over the lead of the corporate project office being
responsible for the controlling and status reporting of
the world wide R&D projects running in Germany, US
and Singapore. Since Oct 2006 is managing the R&D PD
department at Singapore.
Dr Thomas
Daussmann
Vice President & Managing Director
Codexis Laboratories Singapore Pte Ltd
In 1997, Dr Thomas was
awarded his PhD in Microbiology in the University of
Kaiserslautern and Research Centre. His thesis was about
the enzymatic activities of an archaebacterium. Dr Thomas
had always displayed a keen interest in microbiology
since his university days. Upon obtaining his PhD, he
went on to direct the R&D activities at Juelich
Enzyme Products GmbH Managing Director and subsequently,
was appointed the post of managing director at Jülich
Fine Chemicals GmbH.
Prior to this appointment, he has been a member of the
Executive Management Team of Codexis, USA. As of Apr
2007, he is the Vice President & Managing Director of
Codexis Laboratories Singapore Pte Ltd, located in
Science Park III. Besides his plentiful publication
works, he has also gave many oral conference
presentation, such as 'Scale-up of biotransformations' at
the University of Manchester, UK in 2000 and the Green
Chemistry Conference at the University of Rostock,
Germany in 2005.
Associate
Professor Catherine Tay
LL.B (Hons), LL.M
Associate Professor
Faculty of Law, National University of Singapore
Advocate and Solicitor
Supreme Court of Singapore
Catherine Tay is an
Associate Professor lecturing law at the National
University of Singapore (NUS), Department of Business
Policy. Prof Tay also lectures medical law and biomedical
ethics in the Faculty of Dentistry, NUS. She supervised
medical students in legal aspects of medical practice in
the Special Study Module at the Faculty of Medicine, NUS.
Prof Tay is an Advocate and Solicitor of the Supreme
Court of Singapore. She is also a barrister-at-law (of
Lincoln’s Inn, United Kingdom). She is an author of
28 law books, including ‘Medical Negligence’.
Prof Tay is a member of the Institutional Review Board of
SingHealth Polyclinics. She is a member of the National
Healthcare Group (NHG) Domain Specific Review Board
tasked to review the scientific and ethical aspects of
research protocols. She was the medical-legal adviser of
the Institute of Mental Health/Woodbridge Hospital. She
was a member of the Research & Ethics Committee of
Alexandra Hospital.
Prof Tay studied law at Queen Mary College, University of
London and graduated with a Bachelor of Laws with Honours
in 1977 and with a Master of Laws in 1979. Prof Tay was
called to the English Bar by Lincoln’s Inn in 1978.
Prof Tay won the Aw Boon Haw and Aw Boon Par Memorial
Prize for the overall best student in 1980 during her
postgraduate practical law course in Singapore. She was
called to the Singapore Bar in 1980.
Prof Tay has published several articles in international
refereed journals, including BIOETHICS, the Hong Kong
Journal of Emergency Medicine, (UK) Journal of Business
Law, (UK) Company Lawyer, (UK) Professional Negligence
and APLAR Journal of Rheumatology.
Prof Tay was a committee member of the editorial board of
the Singapore Accountant Journal, Journal of the
Institute of Certified Public Accountants of Singapore
and the (United Kingdom) The Company Lawyer. She was on
the Board of Overseas Editors for the (United Kingdom)
Journal of Financial Crime, an official publication of
the Cambridge International Symposium on Economic Crime.
Prof Tay was a member of the editorial board of the
“Singapore Polytechnic Graduate Guild Journal”.
She has presented papers at many conferences and seminars
on Business Law, Medical law, Company and Insolvency Laws
both overseas and in Singapore. Prof Tay is an examiner
on law subjects for a number of professional bodies in
Singapore and overseas. She conducts in-house seminars
for hospitals, banks, statutory boards, hotels,
commercial firms and companies, clubs and associations.
Prof Tay is a legal consultant appearing on many
television segments produced by the then Television
Corporation of Singapore. She speaks on legal subjects on
Media Corp radio weekly. She has co-hosted a weekly talk
show “In the Eyes of the Law” on NTUC
RadioHeart. Prof Tay was a consultant to Media Corp
television series on consumer laws “What’s Your
Case” on TV Channel 5.
Prof Tay participates actively in several professional
and charitable organisations for which she has received
several titles and awards including the titles Miss
Singapore-International Charity Queen at the beauty
pageant in 1990 and 1991 and Miss Singapore-World
University Charity Queen in 1992. Prof. Tay was a
committee member of the Advice and Referral Service in
the Singapore Council of Women’s Organisation. In
1990-2000, she was the President of the Business and
Professional Women’s Association,
Singapore. In March 1992, she was a nominee for the Women
of the Year Award. In May 1994, Prof. Tay received the
Paul Harris Fellow Award from Rotary International in
recognition of her community service.
Dr Lee Chee Wee
Chief Executive Officer
Lynk Biotechnologies
Dr Lee received his B.Sc.
and M.Sc. from McGill University, Canada, and his Ph.D.
from the University of Alberta, Canada. He was a
recipient of the Alberta Heritage Foundation Scholarship
for Medical Research (AHFMR) and had carried out his
Post-doctoral Fellowship at Yale Comprehensive Cancer
Centre and Department of Pharmacology at Yale University
School of Medicine, USA. Thereafter he came to Singapore
to pursue his academic career at the Department of
Physiology, National University of Singapore, where he is
currently an Associate Professor.
In addition to his academic achievements, Dr. Lee is also
responsible for the development of the technological
innovations and proof of concept studies that laid the
foundation for the establishment of Lynk Biotechnologies
Pte Ltd and its subsidiary, MediLynk Pte Ltd. He has been
providing scientific and operational leadership for the
two above mentioned companies as the Chief Executive
Officer since inception. Both companies are now fast
becoming the shining stars in this highly sophisticated
and challenging industry.
He is a researcher in the area of drug development with
the Department of Physiology. A/Prof. Lee has over 20
years of experience in drug discovery and development
process, in areas such as drug design, modeling,
validation, screening, in vitro and in vivo testing. He
is an expert in membrane transport, drug delivery
systems, pharmacodynamics, pharmacokinetics, cancer
chemotherapies, protein chemistry, molecular and cellular
physiology. He obtained his B.Sc. and M.Sc. from McGill
University in 1982 and 1985, respectively. Under Alberta
Heritage Foundation for Medical Research Studentship, he
obtained his Ph.D. in Molecular and Cellular Physiology
from University of Alberta in 1989. He was a
post-doctorate fellow at the Department of Pharmacology
at Yale Comprehensive Cancer Research Centre, Yale
University School of Medicine from 1988-1990. He was
recruited by Department of Physiology to join NUS in
1990.
Mr Loh Chee Mun
Senior Vice President,
Biosensors International Group Limited
Mr. Loh Chee Mun is the
Senior Vice President of Biosensors International Group
Limited and is the head of its investor relations and
corporate communications department.
Prior to joining Biosensors in 2000, Mr. Loh was with the
Singapore Government and was responsible for identifying
and developing medical device technology companies
worldwide through investments and management. Since
joining Biosensors, Mr. Loh first served as Head of
corporate business development before serving as Managing
Director of its Singapore operations. In November 2004,
Mr. Loh was promoted to his present position as Senior
Vice President.
Mr. Loh received an honours degree in Electronics
Engineering and a Master’s degree in Medical
Engineering from the National University of Singapore and
has an Executive Master of Business Administration from
the Helsinki School of Economics. Mr. Loh also received a
Graduate diploma in Financial Management from the
Singapore Institute of Management.
Mr Steven Fang
Group CEO CyGenics Ltd
Mr. Fang is intimately
familiar with the healthcare and Biotechnology business,
with over 18 years of management and operational business
development experiences in Asia Pacific and USA. He has
previously worked for Sterling Withthrop Pharmaceuticals,
Baxter Inc and Becton Dickinson Inc, having undertaken
various market development and management assignments in
USA, China, Malaysia, Korea, Taiwan, and the Philippines.
While at Becton Dickinson, he was the General Manager for
SEA.
Mr. Fang has a first degree in Computer Engineering, an
MBA with the University of Hull (U.K.) in Strategic
Business, in Business Globalization, and a post-graduate
degree with INSEAD in M&A. Mr. Fang incorporated
Cordlife in 2001 and have since taken this start-up to
become an internationally recognized and ASX listed
biotechnology company today with a market capitalization
exceeding A$60 million dollar. Mr. Fang is the Group CEO
for Cordlife, Cytomatrix and Cell Sciences representing
its three core Business Divisions in Tissue banking, Cell
therapy, T-Cell production, Theranostic, Cell-based
assaying, Cell growth products and distribution.
Mr Calvin Chu
Manager Synovate Business Consulting
Calvin has led a wide
range of client work since joining Synovate Business
Consulting in 2001, ranging from competitive and growth
strategy, value chain analysis and new market entry, to
pricing analysis and innovation consulting in over 20
countries. As Business Group Director based in Singapore,
he oversees the overall client engagement, including
design, research planning, quality control, intelligence
analysis, and strategic recommendations. He has advised
dozens of multinational clients in the healthcare sector,
covering diverse engagements in healthcare tourism,
hospital facility feasibility, medical publishing,
medical devices, pharmaceutical IP and manufacturing, as
well as venture capital. Calvin has been featured in
publications such as "Asia Pacific Biotech
Review", "Asian Intellectual Property",
"BusinessWeek", "Health tourism: An
introduction", and "Singapore Business
Review", and appears regularly at industry
conferences. He has a B.A. in Psychology & Political
Science from the National University of Singapore and is
currently pursuing his Executive MBA from the University
of Chicago Graduate School of Business."
Dr Paul Su
Managing Director
Sigma-Aldrich
Dr. Su has a PhD degree in
Nutritional Biochemistry from the University of
Tennessee. Dr. Su started his career as a Scientist in
research procedures and methods development. He later
proceeded to manage the QC Department at Sigma-Aldrich in
St. Louis. He was the inventor of the Sigma-Aldrich LIMS
system for managing laboratory data in the Assay Lab.
Dr. Su also developed the first Biochemistry and
Chemistry Co-operative Education program for Universities
and Colleges in the Mid-Western states of the USA. He
would later create the Staffing and Development
department at Sigma-Aldrich, which has over the years,
developed key managers for the company.
In 1997 and 1998, Dr. Su founded the Sigma-Aldrich
offices here in Singapore and Malaysia. Today, the
company has grown from the pioneer days of two employees
to three very successful multi-million dollar companies
covering the Southeast Asia market. During his free time,
this Managing Director for Sigma-Aldrich Southeast Asia
likes to play music with his band and also is an avid
scuba diver.
Dr Nicholas Ng
General Manager
Promega Corporation (Singapore branch)
Dr. Nicholas Ng is the
General Manager of Promega Corporation (Singapore
branch), a leading global supplier of biological reagents
and reagent systems used in research and applied
technology. He has 12 years of regional distribution
channel management in the Asia Pacific region. He
currently heads the Singapore based operation which
houses a regional inventory hub to provide marketing,
logistics and technical support functions for the Asia
Pacific markets. He also serve in a number of
consultative committee in several Singapore institutions.
He holds a MSc (Distinction) in Plant Biotechnology (
University of London), a PhD from John Curtin School of
Medical Research, Australian National University and an
MBA degree. He also holds a Diploma In Education (NUS).
His research work is in the area of chromatin structure
and transcriptional regulation.
Mr. James
Killory
Director of Technical Services,
Singapore Schering Plough Ltd
Mr. James Killory is the
Director of Technical Services, Singapore of Schering
Plough Ltd. He holds Bachelor of Science degrees in
Biology and Chemical Engineering from Syracuse University
as well as a Masters of Science in Chemical Engineering
from the California Institute of Technology.
He is responsible site-wide for directing technical
services such as technology transfer and change in
technical processes for all production facilities and
pilot R&D plant operation, technical validation as
well as technical training systems and programs
Prior to joining Schering Plough in 2001, Mr. Killory was
with Bristol Meyer Squibbs as an Associate Director for
Chemical Development Pilot Plants, Biotage Division of
Dyax as a Production Manager as well as Merck & Co.
as a Senior Engineer. Since joining Schering Plough, Mr.
Killory has served as Director of API Technology Transfer
in World-Wide Technical Services as well as Director of
API Operations, Singapore.
[Back
to Menu at top]
|
|
